Deborah Ann Miller, Chief Legal Officer, on May 28, 2026, sold 5,500 shares in Nuvalent (NUVL) for $593,101. Following the Form 4 filing with the SEC, Miller has control over a total of 59,634 Class A common shares of the company, with 59,634 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1861560/000186874126000004/xslF345X05/ownership.xml
Darlene Noci, Chief Development Officer, on May 28, 2026, sold 5,500 shares in Nuvalent (NUVL) for $592,923. Following the Form 4 filing with the SEC, Noci has control over a total of 58,117 Class A common shares of the company, with 58,117 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1861560/000186214826000005/xslF345X05/ownership.xml
Marissa B Espineli, Interim CFO, on May 29, 2026, sold 19,667 shares in Innodata (INOD) for $2,082,436. Following the Form 4 filing with the SEC, Espineli has control over a total of 28,014 common shares of the company, with 28,014 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/903651/000110465926068962/xslF345X05/tm2616104-2_4seq1.xml
Martine A Rothblatt, Director, Chairperson & CEO, on May 29, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,261,365. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000065/xslF345X05/primarydocument.xml